Postpartum acquired hemophilia A: immunopathogenesis, diagnostic challenges, and treatment with the CyDRi protocol
Pathology & Oncology Research · 04.05.2026 · 32
DOI: 10.3389/pore.2026.1612302 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathology & Oncology Research, online erschienen am 04.05.2026. Verfasst von Ágnes Szappanos und 10 weiteren Autor:innen. Beteiligte Einrichtung: Heart and Vascular Center, Semmelweis University, Budapest, Hungary. Hauptthemen laut MEDLINE: Hemophilia A, Immunosuppressive Agents. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acquired hemophilia A (AHA) is a rare, potentially life-threatening autoimmune bleeding disorder characterized by the development of inhibitory autoantibodies against factor VIII (FVIII). While most commonly diagnosed in the elderly, AHA can also occur in the postpartum period, where it presents unique diagnostic and therapeutic challenges. This review provides a comprehensive overview of the pathogenesis, clinical features, diagnostic approaches, and current therapeutic strategies for postpartum AHA. We highlight the immunological shifts during pregnancy and the postpartum period that may contribute to the breakdown of immune tolerance and the emergence of FVIII autoantibodies. Key aspects of laboratory diagnosis are outlined, including the role of coagulation screening, mixing studies, and inhibitor assays. We compare the efficacy and safety of established immunosuppressive regimens, with a particular focus on the CyDRi protocol—a combination of cyclophosphamide, dexamethasone, and rituximab—which has demonstrated high rates of complete remission with a favorable toxicity profile. To illustrate clinical application, we describe a case of severe postpartum AHA managed successfully with the CyDRi protocol, followed by an uneventful subsequent pregnancy. With timely diagnosis and appropriately tailored immunosuppressive therapy, postpartum AHA can be effectively treated, and favorable hematologic and reproductive outcomes are achievable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
- Department of Rheumatology and Clinical Immunology, Semmelweis University, Budapest, Hungary.
- Fodor Center for Prevention and Healthy Aging, Semmelweis University, Budapest, Hungary.
- Laboratory of Molecular Genetics, Central Hospital of Southern Pest, National Institute for Hematology and Infectious Diseases, Budapest, Hungary.
- Institute of Preventive Medicine and Public Health, Semmelweis University, Budapest, Hungary.
- Doctoral College, Health Sciences Division, Semmelweis University, Budapest, Hungary.
Zitieren
APA
Szappanos, Á., Andrikovics, H., Varga, P., Fekete, M., Fazekas-Pongor, V., Lehoczki, M., Király, V., Vilimi, B., Mikala, G., Bodó, I., & Ceglédi, A. (2026). Postpartum acquired hemophilia A: immunopathogenesis, diagnostic challenges, and treatment with the CyDRi protocol. Pathology & Oncology Research, 32. https://doi.org/10.3389/pore.2026.1612302
Vancouver
Szappanos Á, Andrikovics H, Varga P, Fekete M, Fazekas-Pongor V, Lehoczki M, et al. Postpartum acquired hemophilia A: immunopathogenesis, diagnostic challenges, and treatment with the CyDRi protocol. Pathology & Oncology Research. 2026;32. doi:10.3389/pore.2026.1612302
BibTeX
@article{Szappanos2026,
author = {Szappanos, Ágnes and Andrikovics, Hajnalka and Varga, Péter and Fekete, Mónika and Fazekas-Pongor, Vince and Lehoczki, Márk and Király, Viktória and Vilimi, Beáta and Mikala, Gábor and Bodó, Imre and Ceglédi, Andrea},
title = {Postpartum acquired hemophilia A: immunopathogenesis, diagnostic challenges, and treatment with the CyDRi protocol},
journal = {Pathology & Oncology Research},
year = {2026},
volume = {32},
doi = {10.3389/pore.2026.1612302}
}
EUVIMED